Latest Ai Platforms News

Opyl Limited’s AI platform TrialKey has partnered with UK insurer Innovatrix to launch a pioneering parametric insurance product that protects biotech firms from the financial risks of clinical trial failures.

Harvest Technology Group reports it is one year ahead of its 3-Year Pathway to Profit plan, forecasting a significant reduction in EBITDA loss for FY25 and unveiling plans for its AI-powered NEON platform launch in 1H26.

Opyl Limited has secured strategic collaborations with two leading contract research organisations, integrating its AI-driven TrialKey platform into cardiovascular, oncology, and rare disease clinical trials to enhance trial design and accelerate commercial growth.

Opyl Limited unveils a bold strategic pivot to enhance its AI-driven drug discovery platform, leveraging a vast proprietary dataset and leadership upgrades to redefine clinical trial innovation.

Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.

Nanoveu’s subsidiary EMASS has hit a key milestone with its ECS-DoT chip achieving 50 updates per second in drone flight simulations, enabling smarter, more stable drones with up to 30% longer flight times.

Straker Ltd reports a solid FY25 performance marked by a strategic shift from legacy translation services to AI-powered language verification, underpinned by robust cash reserves and improved profitability.

Smart Parking Limited reports robust H1 FY25 growth driven by a strategic US acquisition and expanding global footprint, underpinned by proprietary AI technology.

Vection Technologies has secured a strategic partnership with Area 12 Consulting, guaranteeing $0.5 million in annual recurring revenue for its Algho AI platform. This deal marks a significant step in expanding Vection's footprint in the generative AI and digital transformation space.

Algorae Pharmaceuticals has partnered with Peter MacCallum Cancer Centre to validate AI-predicted drug combinations across multiple cancer types, aiming to accelerate its oncology pipeline development.

Opyl Limited has successfully raised $1.5 million through an oversubscribed placement to accelerate the growth of its AI-driven clinical trial platform, Trialkey. The capital injection underscores strong investor confidence as the company prepares for a pivotal expansion phase.

InteliCare Holdings has secured a new commercial trial with mecwacare and advanced deployments at Hardi Aged Care sites, underpinning growth in its AI-driven aged care platform amid regulatory changes.